國家衛生研究院 NHRI:Item 3990099045/10550
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12145/12927 (94%)
造訪人次 : 857001      線上人數 : 91
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/10550


    題名: Prediction of hepatitis B virus reactivation in lymphoma patients with resolved hepatitis B virus infection who received rituximab-containing chemotherapy: The roles of antiHBc/antiHBs quantification
    作者: Yang, HC;Tsou, HH;Pei, SN;Chang, CS;Chen, JH;Yao, M;Lin, SJ;Lin, J;Liu, TW;Chen, PJ;Cheng, AL;Hsu, C;Group, Taiwan Cooperative Oncology
    貢獻者: Division of Biostatistics and Bioinformatics;National Institute of Cancer Research
    摘要: Background and Aims: Prophylactic antiviral therapy was recommended to prevent HBV reactivation for lymphoma patients with resolved HBV infection who received rituximab-containing chemotherapy. This study sought to identify high-risk patients by measuring baseline levels of serum anti-HBc and anti-HBs. Methods: We prospectively followed the HBV DNA levels of 197 lymphoma patients with resolved HBV infection who received rituximab-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone)-based chemotherapy and started antiviral therapy upon HBV reactivation, defined as a greater than 10-fold increase in HBV DNA compared with previous nadir levels (www.clinicaltrial.gov identifier: NCT 00931229). Anti-HBc and anti-HBs levels were measured by double antigen sandwich immunoassay and enzyme immunoassay. Receiver operating characteristic curve analysis was used to determine optimal baseline anti-HBc/anti-HBs levels for prediction of HBV reactivation. Results: The median baseline anti-HBc and anti-HBs levels were 4.25 IU/mL (range 0.23–191.86) and 72.3 mIU/mL (range 0–12513.5) for the 192 patients with enough serum samples for analysis. High anti-HBc (>=6.41 IU/mL) and low anti-HBs (<56.48 mIU/mL) were significantly associated with high risk of HBV reactivation (odds ratio 5.42, and 8.87, respectively, p < 0.001). The cumulative incidence of HBV reactivation at 15 months was 45.8% (95% CI 27.3–64.2) for patients with both high anti-HBc and low anti-HBs at baseline (36 of 192 patients) and 3.0% – 9.6% in other patients (p < 0.001). HBV reactivation, when considered as a time-dependent covariate, independently predicted inferior overall survival (HR 2.41, 95% C.I. 1.15–5.05, p = 0.02). Conclusions: Baseline anti-HBc/anti-HBs levels may predict HBV reactivation. Efficacy of prophylactic antiviral therapy for the long-term clinical outcome should be explored.
    日期: 2017
    關聯: Journal of Hepatology. 2017;66(1, Suppl.):S259.
    Link to: http://dx.doi.org/10.1016/S0168-8278(17)30827-9
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0168-8278&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000401056600564
    顯示於類別:[鄒小蕙] 會議論文/會議摘要
    [劉滄梧] 會議論文/會議摘要

    文件中的檔案:

    檔案 大小格式瀏覽次數
    ISI000401056600564.pdf66KbAdobe PDF326檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋